Director of Research, CNRS, Head of the research group "cell biology of antigen presentation" at the Centre d'Immunologie de Marseille and Director of the CNRS Research Group "Immunotargeting of tumors". He received his MD and PhD at the University of Chicago After clinical training at Duke University he was an investigator in cancer immunotherapy at the National Cancer Institute, Bethesda. He is a pioneer in the area of liposome targeting, in particular having developed the technique of attaching proteins such as antibodies to liposomes for the purpose of delivering their contents into selected cell types . He is author of more than 100 articles and reviews. He has been a consultant to several companies involved in drug delivery (Vestar, Pfizer, GlaxoSmithKline, The Liposome Company) and a member of the Scientific Advisory Board of Inex Pharmaceuticals. His current research interests include control of the passage of protein from endocytic vesicles to the cytosol during the process of antigen presentation.
Pharma, Cancer